TransMedics Group, Inc. (TMDX) — Fair Value Analysis

Base-case fair value (P50): $83.54 · Current price: $75.51 · Verdict: Fairly Valued

The Verdict on TMDX

Based on our Monte Carlo simulations, TRANSMEDICS GROUP INC (TMDX) appears Fairly Valued in the current market. Our analysis indicates a median fair value (P50) of $83.54, presenting an +10.6% upside compared to the current trading price of $75.51. While not significantly undervalued, this suggests that the market price of $75.51 still offers a reasonable entry point within the stock's intrinsic value range, with potential for appreciation towards its calculated median fair value. The +10.6% figure highlights this potential without suggesting extreme mispricing.

How TMDX stacks up against peers

TMDX is categorized with an average quality tier, reflecting its operational and financial health relative to its sector. This designation implies a balanced risk-reward profile, where its financial metrics and business performance are neither exceptionally strong nor concerning when benchmarked against industry standards. The Monte Carlo simulation, which anchors TMDX's median fair value at $83.54, inherently accounts for these fundamental characteristics. An average quality tier, combined with the stock trading at $75.51 — below its $83.54 median fair value — suggests that while there are no glaring red flags, future performance and market sentiment will dictate whether TMDX can consistently trade above its current mark and realize the implied +10.6%.

What this means for investors

For investors considering TMDX, the assessment that it is Fairly Valued with a median fair value of $83.54 above the current $75.51 indicates a solid, rather than spectacular, opportunity. The implied +10.6% suggests some room for growth, though it's important to recognize that an average quality tier means fundamental improvements would be key for sustained outperformance. While a downside scenario is always possible, our Monte Carlo framework highlights the potential for TMDX to gradually converge towards its median fair value. For a deeper understanding of the full probability distribution, including potential bear and bull cases for TMDX, sign up for a free FairCurve account.

Frequently Asked Questions

Is TMDX overvalued or undervalued right now?

Based on our Monte Carlo simulations, TRANSMEDICS GROUP INC (TMDX) is considered Fairly Valued, with a median fair value of $83.54 which is above its current price of $75.51.

What is the bear case and bull case for TMDX?

The full Monte Carlo distribution, including the bear case (P10 target) and bull case (P90 target), along with the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios publicly.

How does FairCurve calculate TMDX's fair value?

FairCurve calculates TMDX's fair value using Monte Carlo simulations, running thousands of forward scenarios to generate a comprehensive distribution of potential outcomes for its intrinsic value.

How can I track TMDX's fair value as it changes?

You can add TMDX to a free FairCurve watchlist to receive daily fair value updates and instant re-valuation alerts when new earnings or significant fundamental data are released.